RSS
29 Aug 2020

FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma

Author: admintech | Filed under: Press Release

STOCKHOLM, Aug. 29, 2020 /PRNewswire/ — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides’ New Drug Application seeking approval of melflufen (INN melphalan flufenamide), in…

This entry was posted on Saturday, August 29th, 2020 at 7:11 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»